#3

OIPE JC181
MAY 29 2001
PATENT & TRADEMARK OFFICE

SEQUENCE LISTING

<110> Nycomed Imaging AS

<120> Improvements in or relating to diagnostic/therapeutic agents

<130> REF/Klaveness/054

<140> US 08/960,054
<141> 1997-10-29

<160> 25

<170> PatentIn Ver. 2.1

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RGDC-Mal-PEG3400-DSPE

<400> 1
Arg Gly Asp Cys
1

<210> 2
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Peptide comprising phosphatidylserine-binding and heparin-binding sections

<400> 2
Phe Asn Phe Arg Leu Lys Ala Gly Gln
Lys Ile Arg Phe Gly Ala Ala
1 5
10 15

Ala Trp Glu Pro Pro Arg Ala Arg Ile

20 25

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Heparin-binding
peptide

<400> 3
Trp Glu Pro Pro Arg Ala Arg Ile

1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Linker sequence

<220>
<221> MOD_RES
<222> (1)
<223> MTX-phenylalanine

<400> 4
Phe Lys Leu Arg Leu Cys

1 5

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Heparin
sulphate binding peptide

<400> 5
Lys Arg Lys Arg

1

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fibronectin
peptide

<400> 6
Trp Gln Pro Pro Arg Ala Arg Ile

1 5

<210> 7
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide
consisting of a heparin sulphate binding peptide
and a fibronectin peptide

<220>
<221> MOD_RES

<222> (1)
<223> Dipalmitoyl-lysine

<400> 7
Lys Lys Arg Lys Arg Trp Gln Pro Pro
Arg Ala Arg Ile
1 5
10

<210> 8
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Fibronectin
peptide sequence

<400> 8
Phe Asn Phe Arg Leu Lys Ala Gly Gln
Lys Ile Arg Phe Gly Gly Gly
1 5
10 15

Gly Trp Gln Pro Pro Arg Ala Ile

20

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Biotinylated
endothelin-1 peptide

<220>
<221> MOD_RES
<222> (1)
<223> Biotin-D-Trp

<400> 9
Trp Leu Asp Ile Ile Trp

1 5

<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Biotinylated
fibrin-anti-polymerant peptide

<220>
<221> MOD_RES
<222> (1)
<223> Biotinylated-Gly

<220>
<221> MOD_RES
<222> (10)
<223> AMIDATION

<400> 10
Gly Pro Arg Pro Pro Glu Arg His Gln
Ser
1 5
10

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
containing RGD sequence and
fluorescein reporter
group

<220>

<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> Acetyl-RGD-K-fluorescein side
chain

<400> 11
Lys Lys Lys Lys Gly

1 5

<210> 12
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Endothelial
cell binding lipopeptide

<220>
<221> MOD_RES
<222> (1)
<223> 2-n-hexadecylstearyl-Lys

<220>
<221> MOD_RES
<222> (18)
<223> AMIDATION

<400> 12
Lys Leu Ala Leu Lys Leu Ala Leu Lys
Ala Leu Lys Ala Ala Leu Lys
1 5
10 15

Leu Ala

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
functionalised with captopril

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> Amide linked via side chain to
captopril

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

<400> 13
Lys Lys Lys Lys

1

<210> 14
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
with an affinity for
endothelial cells

<220>
<221> MOD_RES
<222> (1)

<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> Acp

<220>
<221> MOD_RES
<222> (13)
<223> AMIDATION

<400> 14
Lys Lys Lys Xaa Ile Arg Arg Val Ala
Arg Pro Pro Leu
 1   5
10

<210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
     comprising an interleukin-1
receptor binding
     peptide

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<400> 15
Lys Gly Asp Trp Asp Gln Phe Gly Leu
Trp Arg Gly Ala Ala
 1   5
10

<210> 16
<211> 12
<212> PRT

<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> Dabsyl-Tyr

<220>
<221> MOD_RES
<222> (10)
<223> RGDS chain linked via NH2 group
of lysine

<220>
<223> Description of Artificial
Sequence:Branched core
peptide comprising a dabsylated
atherosclerotic
plaque-binding sequence and
RGDS

<400> 16
Tyr Arg Ala Leu Val Asp Thr Leu Lys
Lys Gly Cys
1 5
10

<210> 17
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)
<223> Biotinylated

<400> 17
gaaaggtagt ggggtcgtgt gccgg
25

<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide
with affinity for thrombi

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (15)
<223> AMIDATION

<400> 18
Lys Asn Asp Gly Asp Phe Glu Glu Ile
Pro Glu Glu Tyr Leu Gln
1 5
10 15

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (5)
<223> Biotinylated-Lys

<400> 19
Lys Trp Lys Lys Lys Gly

1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Thiol-functionalised
lipid molecule

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> Acp

<400> 20
Lys Lys Lys Xaa Cys

1 5

<210> 21
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
functionalised with atenolol

<220>
<221> MOD_RES
<222> (1)

<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked
via amide bond to
atenolol

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

<400> 21
Lys Lys Lys Lys

1

<210> 22
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Lipopeptide
containing folic acid

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked
via amide bond to
folic acid

<400> 22
Lys Lys Lys Lys

1

<210> 23
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide containing a derivative of bestatin

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked via amide bond to derivative of bestatin

<400> 23
Lys Lys Lys Lys

1

<210> 24
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Lipopeptide containing chlorambucil

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked via amide bond to chlorambucil

<400> 24
Lys Lys Lys Lys

1

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Lipopeptide functionalised with sulfisoxazole

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

<220>
<221> MOD_RES
<222> (4)

<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked
via amide bond to
sulfisoxazole

<400> 25
Lys Lys Lys Lys

1

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Atherosclerotic
plaque-binding peptide

<400> 26
Tyr Arg Ala Leu Val Asp Thr Leu Lys

1 5

<210> 27
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Atherosclerotic
plaque-binding peptide

<400> 27
Tyr Ala Lys Phe Arg Glu Thr Leu Glu
Asp Thr Arg Asp Arg Met Tyr
1 5
10 15

<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Atherosclerotic plaque-binding peptide

<400> 28
Arg Ala Leu Val Asp Thr Glu Phe Lys Val Lys Gln Glu Ala Gly Ala
1 5 10 15
Lys

<210> 29
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Thrombus binding peptide

<400> 29
Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10

<210> 30
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Thrombus

binding peptide

<400> 30
Gly Pro Arg Gly

1

<210> 31
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Platelet binding peptide

<400> 31
Pro Leu Tyr Lys Lys Ile Ile Lys Lys Leu Leu Glu Ser
1 5 10